Interstitial fluid flow in cancer: Implications for disease progression and treatment

Cancer Management and Research

Volumn 6, Issue 1, 2014, Pages 317-318

  Munson, Jennifer M ^a   Shieh, Adrian C ^b  

^a University of Virginia   (United States)

^b DREXEL UNIVERSITY   (United States)

Author keywords

Interstitial flow; Invasion; Therapeutics; Tumor microenvironment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CARMUSTINE; N,N DIMETHYLFORMAMIDE; PACLITAXEL; PENTOXIFYLLINE;

ANGIOGENESIS; ASTROCYTOMA; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL ACTIVATION; CELL GROWTH; CELL PROLIFERATION; CHONDROSARCOMA; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; EXTRACELLULAR MATRIX; FIBROBLAST; FLUID FLOW; GLIOMA; HUMAN; IN VIVO STUDY; INTERSTITIAL FLUID; KIDNEY CARCINOMA; LYMPHANGIOGENESIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NONHUMAN; OSTEOSARCOMA; OVARY CARCINOMA; REVIEW; STROMA; TUMOR INVASION; TUMOR MICROENVIRONMENT; UTERINE CERVIX CARCINOMA;

EID: 84925258395     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S65444     Document Type: Review

References (117)

1. Correia AL, Bissell M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 2012;15(1-2): 39-49.
2. Hazlehurst LA, Landowski TH, Dalton W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 2003;22(47):7396-7402.
3. Butcher DT, Alliston T, Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009;9(2):108-122.
4. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10): 806-813.
5. Teo CS, Hor Keong Tan W, Lee T, Wang C.H. Transient interstitial fluid flow in brain tumors: effect on drug delivery. Chem Eng Sci. 2005;60(17):4803-4821.
6. Paszek MJ, Zahir N, Johnson KR, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241-254.
7. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891-906.
8. Yu H, Mouw JK, Weaver V.M. Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol. 2011;21(1):47-56.
9. Kumar S, Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009;28(1-2): 113-127.
10. Boucher Y, Baxter LT, Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990;50(15):4478-4484.
11. Baxter LT, Jain R.K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989;37(1):77-104.
12. Boucher Y, Salehi H, Witwer B, Harsh GR, Jain R.K. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer. 1997;75(6):829-836.
13. Ariffin AB, Forde PF, Jahangeer S, Arif AB, Soden DM, Hinchion J. Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res. 2014;74(10):2655-2662.
14. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain R.K. Macro-and microscopic fluid transport in living tissues: application to solid tumors. AIChE J. 1997;43(3):818-834.
15. Butler TP, Grantham FH, Gullino P.M. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res. 1975; 35(11 Part 1):3084-3088.
16. Chary SR, Jain R.K. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc Natl Acad Sci U S.A. 1989;86(14):5385-5389.
17. Pathak AP, Artemov D, Ward BD, Jackson DG, Neeman M, Bhujwalla Z.M. Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by MRI. Cancer Res. 2005;64(4):1425-1432.
18. Hompland T, Ellingsen C, Øvrebø KM, Rofstad E.K. Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI. Cancer Res. 2012;72(19): 4899-4908.
19. Dafni H, Israely T, Bhujwalla ZM, Benjamin JE, Neeman N. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin. Cancer Res. 2002;62(22):6731-6739.
20. Baxter LT, Jain R.K. Transport of fluid and macromolecules in tumors. I.V. A microscopic model of the perivascular distribution. Microvasc Res. 1991;41(2):252-272.
21. Zhao J, Salmon H, Sarntinoranont M. Effect of heterogeneous vasculature on interstitial transport within a solid tumor. Microvasc Res. 2007;73(3):224-236.
22. Welter M, Rieger H. Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PLoS One. 2013;8(8):e70395.
23. Soltani M, Chen P. Numerical modeling of fluid flow in solid tumors. PLoS One. 2011;6(6):e20344.
24. Gromov P, Gromova I, Olsen CJ, et al. Tumor interstitial fluid-a treasure trove of cancer biomarkers. Biochim Biophys Acta. 2013;1834(11): 2259-2270.
25. Lee I, Boucher Y, Demhartner TJ, Jain R.K. Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer. 1994;69(3):492-496.
26. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
27. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
28. Soltani M, Chen P. Numerical modeling of interstitial fluid flow coupled with blood flow through a remodeled solid tumor microvascular network. PLoS One. 2013;8(6):e67025.
29. Stapleton S, Milosevic M, Allen C, et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS One. 2013;8(12):e81157.
30. Sleeman J, Schmid A, Thiele W. Tumor lymphatics. Semin Cancer Biol. 2009;19(5):285-297.
31. Farnsworth RH, Achen MG, Stacker S.A. Lymphatic endothelium: an important interactive surface for malignant cells. Pulm Pharmacol Ther. 2006;19(1):51-60.
32. Hanahan D, Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
33. Boucher Y, Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 1992;52(1):5110-5114.
34. Provenzano PP, Hingorani S.R. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013;108(1):1-8.
35. Lunt SJ, Kalliomaki TM, Brown A, Yang VX, Milosevic M, Hill R.P. Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer. 2008;8:2.
36. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093-1102.
37. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395-406.
38. Reed RK, Rubin K. Transcapillary exchange: role and importance of the interstitial fluid pressure and the extracellular matrix. Cardiovasc Res. 2010;87(2):211-217.
39. Pathak A, Kumar S. Biophysical regulation of tumor cell invasion: moving beyond matrix stiffness. Integr Biol (Camb). 2011;3(4):267-278.
40. Kaal EC, Vecht C.J. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16(6):593-600.
41. Wiig H, Swartz M.A. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev. 2012;92(3):1005-1060.
42. Wu M, Swartz M. Modeling tumor microenvironments in vitro. J Biomech Eng. 2014;136(2):1-7.
43. Polacheck WJ, German AE, Mammoto A, Ingber DE, Kamm R.D. Mechanotransduction of fluid stresses governs 3D cell migration. Proc Natl Acad Sci U S.A. 2014;111(7):2447-2452.
44. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz M.A. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via IF and autocrine CCR7 signaling. Cancer Cell. 2007;11(6):526-538.
45. Haessler U, Teo JCM, Foretay D, Renaud P, Swartz M.A. Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. Integr Biol (Camb). 2012;4(4):401-409.
46. Munson JM, Bellamkonda RV, Swartz M.A. Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. Cancer Res. 2013;73(5):1536-1546.
47. Qazi H, Shi ZD, Tarbell J.M. Fluid shear stress regulates the invasive potential of glioma cells via modulation of migratory activity and matrix metalloproteinase expression. PLoS One. 2011; 6(5):e20348.
48. Fleury ME, Boardman KC, Swartz M.A. Autologous morphogen gradients by subtle interstitial flow and matrix interactions. Biophys J. 2006;91(1):113-121.
49. Tien J, Truslow JG, Nelson C.M. Modulation of invasive phenotype by interstitial pressure-driven convection in aggregates of human breast cancer cells. PLoS One. 2012;7(9):e45191.
50. Polacheck WJ, Charest JL, Kamm R.D. Interstitial flow influences direction of tumor cell migration through competing mechanisms. Proc Natl Acad Sci U S.A. 2011;108(27):11115-11120.
51. Pathak AP, Artemov D, Neeman M, Bhujwalla Z.M. Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res. 2006;66(10):5151-5158.
52. Linninger AA, Xenos M, Zhu DC, Somayaji MR, Kondapalli S, Penn R.D. Cerebrospinal fluid flow in the normal and hydrocephalic human brain. IEEE Trans Biomed Eng. 2007;54(2):291-302.
53. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol. 2007;170(2):774-786.
54. Geer CP, Grossman S.A. Interstitial fluid flow along white matter tracts: a potentially important mechanism for the dissemination of primary brain tumors. J Neurooncol. 1997;32(3):193-201.
55. Young SRL, Riley RG, Kim J, Pavalko F.M. Focal adhesion kinase is important for fluid shear stress-induced mechanotransduction in osteoblasts. J Bone Miner Res. 2009;24(3):411-424.
56. Kaiser S, Jossen V, Schirmaier C, et al. Fluid flow and cell proliferation of mesenchymal adipose-derived stem cells in small-scale, stirred, single-use bioreactors. Chemie Ing Tech. 2013;85(1-2): 95-102.
57. Chang SF, Chang CA, Lee DY, et al. Tumor cell cycle arrest induced by shear stress: roles of integrins and Smad. Proc Natl Acad Sci U S.A. 2008;105(10):3927-3932.
58. Demou Z.N. Gene expression profiles in 3D tumor analogs indicate compressive strain differentially enhances metastatic potential. Ann Biomed Eng. 2010;38(11):3509-3520.
59. Chien S. Mechanotransduction and endothelial cell homeostasis: the wisdom of the cell. Am J Physiol Heart Circ Physiol. 2007;292(3): H1209-H1224.
60. Miteva DO, Rutkowski JM, Dixon JB, Kilarski W, Shields JD, Swartz M.A. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ Res. 2010;106(5): 920-931.
61. Shi ZD, Wang H, Tarbell J.M. Heparan sulfate proteoglycans mediate interstitial flow mechanotransduction regulating MMP-13 expression and cell motility via FAK-ERK in 3D collagen. PLoS One. 2011;6(1):e15956.
62. Rutkowski JM, Swartz M.A. A driving force for change: interstitial flow as a morphoregulator. Trends Cell Biol. 2007;17(1):44-50.
63. Paszek MJ, Boettiger D, Weaver VM, Hammer D.A. Integrin clustering is driven by mechanical resistance from the glycocalyx and the substrate. PLoS Comput Biol. 2009;5(12):e1000604.
64. Qazi H, Palomino R, Shi ZD, Munn LL, Tarbell J.M. Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion. Integr Biol (Camb). 2013;5(11):1334-1343.
65. Toftgård R. Two sides to cilia in cancer. Nat Med. 2009;15(9): 994-996.
66. Michaud EJ, Yoder B.K. The primary cilium in cell signaling and cancer. Cancer Res. 2006;66(13):6463-6467.
67. Schäfer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008;9(8):628-638.
68. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev. 2009;19(1):67-73.
69. Ng CP, Hinz B, Swartz M.A. Interstitial fluid flow induces myofibroblast differentiation and collagen alignment in vitro. J Cell Sci. 2005;118 Pt 20:4731-4739.
70. Shieh AC, Rozansky HA, Hinz B, Swartz M.A. Tumor cell invasion is promoted by interstitial flow-induced matrix priming by stromal fibroblasts. Cancer Res. 2011;71(3):790-800.
71. Bhowmick NA, Neilson EG, Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332-337.
72. Boardman KC, Swartz M.A. Interstitial flow as a guide for lymphangiogenesis. Circ Res. 2003;92(7):801-808.
73. Helm CE, Zisch A, Swartz M.A. Engineered blood and lymphatic capillaries in 3-D VEGF-fibrin-collagen matrices with interstitial flow. Biotechnol Bioeng. 2007;96(1):167-176.
74. Song JW, Munn L.L. Fluid forces control endothelial sprouting. Proc Natl Acad Sci U S.A. 2011;108(37):15342-15347.
75. Dela Paz NG, Walshe TE, Leach LL, Saint-Geniez M, D'Amore P.A. Role of shear-stress-induced VEGF expression in endothelial cell survival. J Cell Sci. 2012;125 Pt 4:831-843.
76. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz M.A. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009;69(1):349-357.
77. Nasu R, Kimura H, Akagi K, Murata T, Tanaka Y. Blood flow influences vascular growth during tumour angiogenesis. Br J Cancer. 1999;79(5-6):780-786.
78. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
79. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205-2218.
80. Wu J, Long Q, Xu S, Padhani A.R. Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech. 2009;42(6):712-721.
81. Leunig M, Goetz AE, Dellian M, Dell M, Gamarra F, Jain R.K. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992;52(2):487-490.
82. Znati CA, Rosenstein M, Boucher Y, et al. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft advances in brief effect of radiation on interstitial fluid pressure and oxygenation in a human. Cancer Res. 1996;56(5):964-968.
83. Hall WA, Rustamzadeh E, Asher A.L. Convection-enhanced delivery in clinical trials. Neurosurg Focus. 2003;14(2):e2.
84. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S.A. 1994;91(6):2076-2080.
85. Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004;64(7):2572-2579.
86. Vandergrift WA, Patel SJ, Nicholas JS, Varma A.K. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg Focus. 2006;20(4):E13.
87. Smith JH, Humphrey J.A. Interstitial transport and transvascular fluid exchange during infusion into brain and tumor tissue. Microvasc Res. 2007;73(1):58-73.
88. Kong G, Braun RD, Dewhirst M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 2000;60(16):4440-4405.
89. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev. 2008;60(10):1193-1208.
90. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998; 352(9123):179-184.
91. Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.
92. Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7(6):383-388.
93. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454(7204):656-660.
94. Das S, Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci. 2008;1131:235-241.
95. Fuster MM, Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5(7):526-542.
96. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis E.P. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics. 2009;8(4):661-669.
97. Wang Z, Wang C, Huang X, Shen Y, Shen J, Ying K. Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients. Biochim Biophys Acta. 2012;1824(4):692-700.
98. Celis JE, Gromov P, Cabezón T, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics. 2004;3(4):327-344.
99. Teplyuk NM, Mollenhauer B, Gabriely G, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012;14(6):689-700.
100. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087-2092.
101. Clayton A. Cancer cells use exosomes as tools to manipulate immunity and the microenvironment. Oncoimmunology. 2012;1(1):78-80.
102. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006;66(4):1883-1890.
103. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-234.
104. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29(4):297-307.
105. Lucio-Eterovic AK, Piao Y, de Groot J.F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(14):4589-4599.
106. Nakasone ES, Askautrud HA, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012;21(4):488-503.
107. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004;28(1):38-44.
108. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond). 2002;102(4):417-424.
109. Ghajar CM, Peinado H, Mori H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807-817.
110. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69-82.
111. Baumgartner G, Gomar-Höss C, Sakr L, Ulsperger E, Wogritsch C. The impact of extracellular matrix on the chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998;131(1):85-99.
112. Rong Y, Durden DL, Van Meir EG, Brat D.J. "Pseudopalisading" necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65(6):529-539.
113. Mueller SN, Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol. 2009;9(9):618-629.
114. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade S.R. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012;104(17):1320-1334.
115. Brennen WN, Isaacs JT, Denmeade S.R. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11(2):257-366.
116. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One. 2009;4(11):e7965.
117. Avraham-Chakim L, Elad D, Zaretsky U, Kloog Y, Jaffa A, Grisaru D. Fluid-flow induced wall shear stress and epithelial ovarian cancer peritoneal spreading. PLoS One. 2013;8(4):e60965.